Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics
- 17 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 37 (7), 1-10
- https://doi.org/10.1007/s11095-020-02854-4
Abstract
Background and Objective Fluoxetine, antidepressant widely-used during pregnancy, is a selective inhibitor for P-glycoprotein (P-gp). Fexofenadine, anin vivoP-gp probe, is an antihistamine drug for seasonal allergic rhinitis and chronic urticaria treatment during pregnancy and it is available as a racemic mixture. This study evaluated the chiral discrimination of P-gp investigating the effect of fluoxetine on maternal-fetal pharmacokinetics of fexofenadine. Methods Healthy parturient women received either a single oral dose of 60 mg racemic fexofenadine (Control group;n = 8) or a single oral dose of 40 mg racemic fluoxetine 3 h before a single oral dose of 60 mg racemic fexofenadine (Interaction group;n = 8). Maternal blood and urine samples were collected up to 48 h after fexofenadine administration. At delivery, maternal-placental-fetal blood samples were collected. Results The maternal pharmacokinetics of fexofenadine was enantioselective (AUC(R-(+)/S-(-))(0-infinity) similar to 1.5) in both control and interaction groups. Fluoxetine increased AUC(0-infinity)(267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine. However, the transplacental transfer of fexofenadine is low (similar to 16%), non-enantioselective and non-influenced by fluoxetine. Conclusions A single oral dose of 40 mg fluoxetine inhibited the intestinal P-gp mediated transport of S-(-)-fexofenadine to a greater extent than R-(+)-fexofenadine in parturient women. However, the placental P-gp did not discriminate fexofenadine enantiomers and was not inhibited by fluoxetine.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303142/2019-7)
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 38 references indexed in Scilit:
- Prenatal anxiety effects: A reviewInfant Behavior and Development, 2017
- Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current EvidenceCNS Drugs, 2016
- Treatment of resistant human colon cancer xenografts by a fluoxetine–doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimenCancer Letters, 2009
- Increasing use of antidepressants in pregnancyAmerican Journal of Obstetrics and Gynecology, 2007
- Perinatal DepressionObstetrics & Gynecology, 2005
- Stereochemistry in Drug ActionThe Primary Care Companion For CNS Disorders, 2003
- Inhibition of P-Glycoprotein by Newer AntidepressantsJournal of Pharmacology and Experimental Therapeutics, 2003
- Great Expectations in Stereochemistry: Focus on AntidepressantsCNS Spectrums, 2002
- Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.Cellular and Molecular Neurobiology, 1999
- Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivoNeuropharmacology, 1992